Filtered By:
Condition: Heart Disease
Drug: Aspirin

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 179 results found since Jan 2013.

An Aspirin a Day: Is the Benefit Worth the Risk?
Studies have shown that aspirin, the age old remedy for pain and fever, also thins the blood. Because of this property, it can also help to lower the chances of a heart attack or a stroke caused by a blood clot in the brain. And, although research has found that it only works in certain people (specifically, those with a history of heart attack or stroke) many Americans are inappropriately taking daily, low doses of aspirin as a preventative measure. In fact, researchers have found that about 12 percent of the of nearly 69,000 U.S. adults taking aspirin on a long-term basis should not have received the prescription in the ...
Source: Healthy Living - The Huffington Post - March 13, 2015 Category: Consumer Health News Source Type: news

Nanoparticles used to treat damaged arteries
Conclusion This exciting study in mice has shown that nanoparticles can be manufactured to target the plaques that form in atherosclerosis, and help stabilise them. It appears that the nanoparticles honed in on the plaques, rather than affecting other organs such as the spleen or liver, which gives an early indication that there may not be substantial side effects. However, it will be necessary to see if the same holds true for other organs. As with all mice studies, they give an indication of the likely biological effects of a new technique, but they do not provide the full picture of what may happen in humans, especially...
Source: NHS News Feed - February 19, 2015 Category: Consumer Health News Tags: Heart/lungs Medical practice Medication Source Type: news

Director's Comments: Aspirin: Initial Heart Attack and Stroke
Listen to the NLM Director's Comments on Aspirin: Initial Heart Attack and Stroke. The transcript is also available. A daily, low dose aspirin may not prevent heart attacks, strokes as well as some other heart disease related conditions for older adults, suggests a comprehensive Japanese study and an accompanying editorial recently published in the Journal of the American Medical Association.
Source: What's New on MedlinePlus - January 27, 2015 Category: Consumer Health News Source Type: news

Well: Many Who Take a Daily Aspirin Don’t Need It
Many healthy people take a daily aspirin to reduce the risk of heart disease and stroke, but a new study has found that more than 11 percent of them should not be doing so.
Source: NYT - January 13, 2015 Category: American Health Authors: By NICHOLAS BAKALAR Tags: Heart Body Aspirin Featured Source Type: news

Wholegrains, not just porridge, may increase life
Conclusion This analysis of two large prospective cohort studies from the US has found an association between higher wholegrain intake and a reduced risk of death during follow-up, particularly from heart disease. The study benefits from its large size (more than 100,000 participants) and long duration, as well as the thorough collection of information on the participants as the study progressed (prospective data collection). Our diets and lifestyles are very complex, and it is very difficult to entirely isolate the effect of one dietary component and remove the effect of all other factors. However, the researchers have ...
Source: NHS News Feed - January 6, 2015 Category: Consumer Health News Tags: Heart/lungs Food/diet Source Type: news

New approaches to inhibiting platelets and coagulation.
Abstract Ischemic heart disease and stroke are major causes of death and morbidity worldwide. Coronary and cerebrovascular events are a consequence of thrombus formation caused by atherosclerotic plaque rupture or embolism, both of which result from platelet activation and aggregation and thrombin-mediated fibrin generation via the coagulation cascade. Current and emerging antiplatelet and anticoagulant agents are evolving rapidly. The use of aspirin for primary prevention continues to be controversial, as are the doses appropriate for secondary prevention. Development of new oral and intravenous adenosine diphosp...
Source: Annual Review of Pharmacology and Toxicology - January 6, 2015 Category: Drugs & Pharmacology Authors: Depta JP, Bhatt DL Tags: Annu Rev Pharmacol Toxicol Source Type: research

The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders
Cardiovascular disease (CVD) includes a number of conditions such as myocardial infarction, coronary heart disease, stroke, and venous thromboembolism. CVD is a leading health problem worldwide and a major cause of mortality, morbidity, and disability; it is also associated with high healthcare costs. The incidence of CVD is predicted to increase in the forthcoming years, and thus it is crucial that physicians are aware of the benefits and limitations of the available therapies to ensure patients receive optimized treatment.
Source: Thrombosis Research - December 12, 2014 Category: Hematology Authors: A.T. Cohen, S. Imfeld, J. Markham, S. Granziera Tags: Review Article Source Type: research

Low-dose aspirin lowers disease risk for many women, study finds
According to a study out of the Netherlands, women who take low-dose aspirin have a lower risk of heart disease and other conditions. Also, new advice for people who suffer from a minor stroke. Eboni Williams reports on the day's top health news.
Source: Health News: CBSNews.com - December 5, 2014 Category: Consumer Health News Source Type: news

Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study
Conclusions Among patients with an ischaemic stroke while taking aspirin, clopidogrel initiation was associated with fewer recurrent vascular events than aspirin reinitiation.
Source: BMJ Open - December 2, 2014 Category: Journals (General) Authors: Lee, M., Wu, Y.-L., Saver, J. L., Lee, H.-C., Lee, J.-D., Chang, K.-C., Wu, C.-Y., Lee, T.-H., Wang, H.-H., Rao, N. M., Ovbiagele, B. Tags: Open access, Cardiovascular medicine, Epidemiology, Neurology Research Source Type: research

Questions linger over POISE-2 and perioperative aspirin management
Commentary on: Devereaux PJ, Mrkobrada M, Sessler DI, et al.. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014;370:1494–503. Context Aspirin therapy for secondary prevention in patients with cardiovascular (CV) disease was catalysed by the Antithrombotic Trialists’ Collaboration meta-analysis in which antiplatelet therapy (primarily aspirin) demonstrated a 22% reduction in mortality from any vascular cause.1 Based on this meta-analysis and American Heart Association (AHA) guidelines, high-risk patients (those with coronary artery, cerebrovascular or peripheral vascular disease) should be pre...
Source: Evidence-Based Medicine - November 19, 2014 Category: Internal Medicine Authors: Gerstein, N. S., Charlton, G. A. Tags: Epidemiologic studies, Drugs: cardiovascular system, Stroke, Interventional cardiology, Ischaemic heart disease Therapeutics Source Type: research

NIH-led study explores prevention of heart disease in HIV-infected people
(NIH/National Institute of Allergy and Infectious Diseases) The National Institutes of Health has launched a clinical trial to assess the effects of aspirin and cholesterol-lowering drugs, or statins, on preventing cardiovascular disease in people with long-term HIV infections. This group, which includes people on antiretroviral therapy as well as 'elite controllers' who can limit the virus without antiretroviral therapy, have a higher risk of developing heart disease and stroke compared to the general population.
Source: EurekAlert! - Medicine and Health - October 28, 2014 Category: Global & Universal Source Type: news

Predictors of Mortality in Patients With Lacunar Stroke in the Secondary Prevention of Small Subcortical Strokes Trial Clinical Sciences
Conclusions— Unexpected interactions between assigned antiplatelet therapy and each of ischemic heart disease and normal/prehypertensive status accounted for increased mortality among patients with recent lacunar stroke given dual antiplatelet therapy. Despite extensive exploratory analyses, the mechanisms underlying these interactions are uncertain. Clinical Trial Registration— URL: http://www.SPS3ClinicalTrials.gov. Unique identifier: NCT00059306.
Source: Stroke - September 22, 2014 Category: Neurology Authors: Sharma, M., Pearce, L. A., Benavente, O. R., Anderson, D. C., Connolly, S. J., Palacio, S., Coffey, C. S., Hart, R. G. Tags: Cerebral Lacunes, Antiplatelets Clinical Sciences Source Type: research

A cluster-randomized controlled trial to evaluate the effects of a simplified cardiovascular management program in Tibet, China and Haryana, India: study design and rationale
DiscussionTo our knowledge, this will be the first study to evaluate the effect of a simplified management program delivered by community health workers with the help of electronic decision support system on improving the health of high cardiovascular disease risk patients. If effective, this intervention strategy can serve as a model that can be implemented, where applicable, in rural China, India, and other resource-constrained areas.Trial registration: The trial was registered in the clinicaltrials.gov database on 30 December, 2011 and the registration number is NCT01503814.
Source: BMC Public Health - Latest articles - September 6, 2014 Category: Consumer Health News Authors: Vamadevan AjayMaoyi TianHao ChenYangfeng WuXian LiDanzeng DunzhuMohammed AliNikhil TandonAnand KrishnanDorairaj PrabhakaranLijing Yan Source Type: research